Assortment of medicinal preparations and features of practical use in mucormicosis

In recent years, there has been an increase in the incidence of fungal infections, including deep mycoses. Key risk factors for developing fungal infections include chemotherapy and immunosuppression; decompensated diabetes mellitus; renal failure; septicemia in immunocompromised patients; dehydration, such as severe diarrhea and vomiting; alcoholic cirrhosis of the liver; cancer; and HIV infection. Treatment for complications of COVID-19 has contributed to the growth of drug resistance in bacteria and fungi. The Mucorales species are characterized by high level resistance to most currently available antifungal drugs. The emergence of severe deep mycoses with high mortality rates necessitates a focus on antifungal resistance, as fungi can become resistant to drugs designed to kill them. The objective of this study was to review the current state of treatment for antifungal infections, identify risk factors for invasive mycoses. 
When this was used method of the review of the literature. A list of antifungal drugs available on the Russian pharmaceutical market is provided. The most common form of mucormycosis is the rhinocerebral form, with a mortality rate reaching 80%. The main treatment includes radical removal of necrotic soft and bone tissue in the lesion, systemic antifungal therapy with liposomal amphotericin B (intravenously) and symptomatic therapy. It is shown that the pharmaceutical market has a limited range of dosage forms and a limited range of antifungal agents. 

1. World Health Organization. WHO priority pathogens list for R&D of new antibiotics: Press release. Geneva. 2017. URL: https://www.who.int/ru/news-room/detail /27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: 13.07.2025). (In Russian).

2. Kubin C. J., McConville T. H., Donald D., Zucker J., May M., Nelson B., Istorico E., Bartram, L., Small-Saunders, J., Sobieszczyk, M. E., Gomez-Simmonds, A., Uhlemann, A.-C. // Characterization of bacterial and fungal infections in hospitalized patients with COVID-19 and factors associated with healthcare-associated infections // Open Forum Infectious Diseases. 2021. 8 (6). ofab201. DOI: 10.1093/ofid/ofab201

3. Aimoldina A. A., Batpenova G. R., Algazina T. O., Kiyan V. S., Pertsukh Yu. S., Amantaev D. M. The current state of dermatophyte resistance to antimycotic drugs // Science and Healthcare 2024. 26 (6). 173–183. DOI: 10.34689/SH.2024.26.6.020 (In Russian).

4. Garcia-Rubio R., Monteiro M., Mellado E. Azole antifungal drugs: mode of action and resistance: reference module in life sciences. Oxford: Elsevier, 2018. 427–437. DOI: 10.1016/B978-0-12-809633-8.20731-0

5. Akimkin V. G., Tutelyan A. V., Shulakova N. I. The mycological iceberg: Recent shifts in the epidemiology of mycoses // Infectious Diseases. 2022. 20 (1). 120–126. DOI: 10.20953/1729-9225-2022-1-120-126 (In Russian).

6. Khostelidi S. N., Vasilieva N. V. A review of international clinical guidelines on the diagnosis and treatment of invasive mycoses associated with rare hyalohyphomycetes // Problems in Medical Mycology. 2025. 27 (2). 15–35. DOI: 10.24412/1999-6780-2025-2-15 35 (In Russian).

7. Zgadzay Y., Kolosova O., Stetsenko A., Wu C., Bruchlen D., Usachev K., Validov Sh., Jenner L., Rogachev A., Yusupov M., Sachs M. S., Guskov A., Yusupov M. E-site drug specificity of the human pathogen Candida albicans ribosome // Science Advances. 2022. 8 (21). DOI: 10.1126/sciadv.abn1062

8. Stepanov A. A., Vasilchenko A. V., Vasilchenko А. S. Subinhibitory effects of 2,4-diacetylphloroglucinol on filamentous fungus Aspergillus fumigatus // Journal of Applied Microbiology. 2013. 134 (12). DOI: 10.1093/jambio/lxad294

9. Kuvarina A. E., Gavryushina I. A., Sykonnikov M. A., Efimenko T. A., Markelova N. N., Bilanenko E. N., Bondarenko S. A., Kokaeva L. Y., Timofeeva A. V., Serebryakova M. V., Barashkova A. S., Rogozhin E. A., Georgieva M. L., Sadykova V. S. Exploring peptaibol’s profile, antifungal, and antitumor activity of Emericellipsin A of Emericellopsis species from soda and saline soils // Molecules. 2022. 27 (5). 1726. DOI: 10.3390/molecules27051736

10. Proshina L. G., Okonenko T. I., Antropova G. A., Zheznyakovskaya L. F., Proshin A. V. Development of ointment with antimicrobial activity from plant materials and its study // IOP Conference Series: Earth and Environmental Science, Vol. 613: The International Scientific and Practical Conference Biotechnology in the Agro-Industrial Complex and Sustainable Environmental Management, 22 October 2020, Veliky Novgorod, Russian Federation. Veliky Novgorod, 2020. DOI: 10.1088/1755-1315/613/1/012116

11. Antifungal agents in clinical and preclinical development: overview and analysis. 2025: World Health Organization. URL: https://www.who.int/ publications/i/item/9789240105140 (Accessed: 13.07.2025).

12. WHO fungal priority pathogens list to guide research, development and public health action 2022: World Health Organization. URL: https://www.who.int/publications /i/item/9789240060241 (Accessed: 13.07.2025).

13. Prakash H., Chakrabarti A. Epidemiology of Mucormycosis in India // Microorganisms. 2021. 9 (3). 523. DOI: 10.3390/microorganisms9030523

14. Seidel D., Simon M., Sprute R., Lubnow M., Evert K., Speer C., Seeßle J., Khatamzas E., Merle U., Behrens C., Blau I. W., Enghard P., Haas C. S., Steinmann J., Kurzai O., Cornely O. A. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals // Mycoses. 2022. 65 (1). 103–109. DOI: 10.1111/myc.13379

15. Popova M. O., Rogacheva Yu. A. Mucormycosis: modern diagnostics and treatment, existing problems and new trends in antifungal therapy // Clinical Microbiology and Antimicrobial Chemotherapy 2021. 23 (3). 226–238. DOI: 10.36488/cmac.2021.3.226238 (In Russian).

16. Abdullozoda J. A., Khodzhamuradov G. M., Shamszoda Kh. A., Khamidov M. G., Tursunov R. A. Organization of comprehensive treatment of the rhinocerebral form of mucormycosis in the post-COVID period // Healthcare of Tajikistan. 2023. 357 (2). 5–11. DOI: 10.52888/0514-2515-2023-357-2-5-11 (In Russian).

17. State register of medicinal products. Retrieved http://grls.rosminzdrav.ru/grls.aspx (Accessed: 15.07.2025). (In Russian).

18. from Infectious diseases: National guideline. Moscow: GEOTAR-Media, 2019. 1104 p. (In Russian).